Melioidosis News and Research

RSS
Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Deadly bacteria can travel to the brain and spinal cord in 24 hours, new study finds

Deadly bacteria can travel to the brain and spinal cord in 24 hours, new study finds

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Emergent BioSolutions sign development agreement

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix closes previously announced registered public offering

Soligenix closes previously announced registered public offering

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome